Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Total Debt (2020 - 2025)

Bioventus (BVS) has disclosed Total Debt for 6 consecutive years, with $279.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Debt fell 16.89% year-over-year to $279.0 million, compared with a TTM value of $279.0 million through Dec 2025, down 16.89%, and an annual FY2025 reading of $279.0 million, down 16.89% over the prior year.
  • Total Debt was $279.0 million for Q4 2025 at Bioventus, down from $322.6 million in the prior quarter.
  • Across five years, Total Debt topped out at $445.6 million in Q2 2023 and bottomed at $162.4 million in Q4 2021.
  • Average Total Debt over 5 years is $346.0 million, with a median of $367.0 million recorded in 2023.
  • The sharpest move saw Total Debt skyrocketed 161.27% in 2022, then dropped 22.28% in 2025.
  • Year by year, Total Debt stood at $357.7 million in 2021, then grew by 16.88% to $418.1 million in 2022, then fell by 12.22% to $367.0 million in 2023, then dropped by 8.55% to $335.6 million in 2024, then dropped by 16.89% to $279.0 million in 2025.
  • Business Quant data shows Total Debt for BVS at $279.0 million in Q4 2025, $322.6 million in Q3 2025, and $297.9 million in Q2 2025.